Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last --
Change Today 0.00 / 0.00%
Volume 0.0
4502 On Other Exchanges
4502 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research and development, manufacture, marketing, and sale of pharmaceutical products worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, central nervous system, immunology and respiratory, general medicine, oncology, gastroenterology, and vaccines. The company has a partnership with Gencia LLC to develop a class of small molecule drugs as potential treatments for hematological and inflammatory diseases; and research collaboration with University College London to identify and validate novel target genes for the treatment of neurodegenerative disease. Takeda Pharmaceutical Company Limited has a strategic drug discovery collaboration; strategic alliance with enGene, Inc.; and partnership with Cour Pharmaceutical Development Company, Inc. The company was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Senior Vice Preside...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited Announces FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix (Vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder

H. Lundbeck A/S and Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 8 to 2 that the companies presented substantial evidence to support the effectiveness of Brintellix (vortioxetine) for treating certain aspects of cognitive dysfunction in adults with Major Depressive Disorder (MDD). Earlier the committee also discussed that cognitive dysfunction in MDD represents an appropriate drug development target. The Advisory Committee provides the FDA with independent expert advice and recommendations. The committee's input will be considered by the Agency in its review of the Brintellix sNDA, which was accepted for review in August 2015. The FDA is expected to make a decision by 28 March 2016. The FDA is not bound by the committee's guidance. Depression can be a combination of multiple symptoms, including cognitive dysfunction. The prevalence of cognitive dysfunction associated with depression is high. According to a three-year prospective study of people treated for depression, cognitive symptoms (defined as diminished ability to think or concentrate and/or indecisiveness) were reported 94% of the time during acute major depressive episodes and 44% of the time during remission. The Advisory Committee reviewed data from the FOCUS and CONNECT studies, which were specifically designed to assess the effect of Brintellix on certain aspects of cognitive dysfunction in adult patients (18-65 years) with MDD. These two 8-week, randomized, double-blind, placebo-controlled studies of Brintellix 10 and 20 mg/day used a neuropsychological test of cognitive performance (the Digit Symbol Substitution Test or DSST). The FDA approved Brintellix on 30 September 2013 for the treatment of MDD in adults. Brintellix is furthermore approved in 64 countries (including Europe, Brazil, Canada, Chile, Mexico, Argentina, South Korea, Turkey, Australia, Hong Kong, Singapore and South Africa).

Takeda Pharmaceutical Company Limited Provides Dividend Guidance for the Fiscal 2015

Takeda Pharmaceutical Company Limited provided dividend guidance for the fiscal 2015. For the year, the company expects year-end dividend of JPY 90 per share against JPY 90 per share paid a year ago.

Mersana Therapeutics and Takeda Expand Partnership to Advance Development of Fleximer Antibody-Drug Conjugates and XMT-1522

Mersana Therapeutics and Takeda Pharmaceutical Company Limited announced that they have entered a new strategic partnership granting Takeda rights to Mersana's lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana's Fleximer antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥5,087.00 JPY -254.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,497 JPY -81.50
Baxter International Inc $36.61 USD +0.73
Becton Dickinson and Co $139.81 USD +4.48
Biogen Inc $247.22 USD +2.11
Merck KGaA €74.08 EUR +2.65
View Industry Companies

Industry Analysis


Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 2.0x
Price/Cash Flow 713.7x
TEV/Sales 1.5x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at